Regeneron Partnering With Ocular May Provide Needed Tech Validation

Beset with clinical trial disappointments in the past year, Ocular Therapeutix Inc. obtained a much-needed validation of its technology Oct. 13 as it announced a collaboration with Regeneron Pharmaceuticals Inc. to develop a sustained-release version of Eylea (aflibercept) with a goal of producing a formulation that will only need to be dosed two or three times a year, rather than every other month.

Currently in preclinical development, the candidate will employ Ocular's proprietary sustained-release hydrogel-based drug delivery depot formulation for intravitreal injection. In...